Lassen Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5510 Morehouse Dr Ste 100, San Diego, Ca...Phone Number
(858) 251-7528Website
www.lassentherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Lassen Therapeutics
Lassen Therapeutics is focused on developing innovative biotherapeutics aimed at improving the lives of patients with serious diseases. The company specializes in creating novel medicines through advanced antibody technologies, particularly targeting interleukin-11 to address conditions like thyroid eye disease and idiopathic pulmonary fibrosis. Their commitment to innovation, transparency, and collaboration drives their mission to deliver life-improving treatments. Lassen Therapeutics is dedicated to building a robust pipeline of breakthrough therapeutics guided by meaningful core values.Explore more
Lassen Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lassen Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Lassen Therapeutics is spiking on competitors!
Lassen Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Lassen Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Lassen Therapeutics
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Lassen Therapeutics recently announced quarterly report
Check if Lassen Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Lassen Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Lassen Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Lassen Therapeutics
Compare insights from companies similar to Lassen Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lassen Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lassen Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lassen Therapeutics.
Lassen Therapeutics financials insights
Gather financial insights about Lassen Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$85M
Lassen Therapeutics Tech Stack
A closer look at the technologies used by Lassen Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Funding
Lassen Therapeutics News & Media
Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease
SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics, LASN01, targeting interleukin-11 receptor (IL-11R) as a potential treatment for fibro-inflammatory diseases such as TED and IPF, and a highly potent, first-in-class monoclonal antibody, LASN500, targeting the interleukin-18 binding protein (IL-18BP) as a potential treatment for cancer, today announced the closing of an oversubscribed Series B financing which raisedLassen Therapeutics Presents Preclinical Data on LASN01, an Anti-IL-11 Receptor Antibody in Development for Treatment of Thyroid Eye Disease at the American Thyroid Association 2023 Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotechnology company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R; LASN01) as a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), and interleukin-18 binding protein (IL-18BP; LASN500), as a potential treatment for cancer, presented new preclinical data on LASN01, for treatment of TED, at the American ThyroiLassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease at the European Respiratory Society (ERS) and European Thyroid Association (ETA) Annual Meetings
SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R, LASN01) as a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), and interleukin-18 binding protein (IL-18BP, LASN500) as a potential treatment for cancer, today announced new clinical and preclinical data generated with LASN01 at the 2023 European
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lassen Therapeutics
Sign Up For FreeTo access detailed company insights
Lassen Therapeutics is focused on developing innovative biotherapeutics aimed at improving the lives of patients with serious diseases. The company specializes in creating novel medicines through advanced antibody technologies, particularly targeting interleukin-11 to address conditions like thyroid eye disease and idiopathic pulmonary fibrosis. Th... Read More
